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Background: Embolization of atherosclerotic debris from the rupture of a vulnerable atherosclerotic plaque occurs
iatrogenically during percutaneous coronary interventions (PCI) and can induce myocardial necrosis. These
microembolizations are detected as high intensity transient signals (HITS) using intracoronary Doppler technology.
Presentation of the hypothesis: In the presented study we will test if abciximab (ReoProW) infusion reduces high
intensity transient signals in patients with stable angina pectoris undergoing PCI in comparison to standard
therapy alone.
Testing the hypothesis: The High Intensity Transient Signals ReoProW (HITS-RP) study will enroll 60 patients. It is a
prospective, single center, randomized, double-blinded, controlled trial. The study is designed to compare the
efficacy of intravenous abciximab administration for reduction of microembolization during elective PCI. Patients
will be randomized in a 1:1 fashion to abciximab or placebo infusion. The primary end point of the HITS-RP-Study is
the number of HITS during PCI measured by intracoronary Doppler wire. Secondary endpoints are bleeding
complications, elevation of cardiac biomarkers or ECG changes after percutaneous coronary interventions, changes
in coronary flow velocity reserve, hs-CRP elevation, any major adverse cardio-vascular event during one month
follow-up.
Implications of the hypothesis: The HITS-RP-Study addresses important questions regarding the efficacy of
intravenous abciximab administration in reducing microembolization and periprocedural complications in stable
angina pectoris patients undergoing PCI.
Trial registration: The trial is registered under www.drks-neu.uniklinik-freiburg.de/drks_web/:DRKS00000603.* Correspondence: daniel.kretzschmar@med.uni-jena.de
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Following percutaneous coronary intervention (PCI) an
increase of cardiac marker enzymes is relatively often
observed and associated with reduced coronary flow vel-
ocity reserve (CFVR) [1]. Serum concentration of cardiac
troponin I (cTNI) was reported to be increased in
30–40% of cases [2]. The troponin rise is the result of
myocardial necrosis during PCI induced by embolization
of atherosclerotic and thrombotic debris during balloon
or stent inflation [3]. Troponin elevation is associated
with dismal prognosis in patients with unstable angina
[4] and PCI [5]. Periprocedural coronary microemboliza-
tion occurs in about 25% of all PCIs. The incidence
ranges from 0 to 70%, depending on the method of as-
sessment [6]. Coronary microembolization is a common
event during several phases during PCI. Even passing of
the stenosis with the stent or balloon may be a vulner-
able phase [7].
The consequences of coronary microembolization are
microinfarctions with an inflammatory response, con-
tractile dysfunction, perfusion-contraction mismatch,
and reduced CFVR [8]. The number of microparticles
correlate to the size of myocardium at risk in patients
with ST-elevation myocardial infarction [9].
The intracoronary Doppler guidewire is a feasible de-
vice for detection and quantification of microembolism
occurring during PCI [10]. In a previous study we could
demonstrate that the incidence of procedural associated
non-ST elevation myocardial infarction (pNSTEMI) is
correlated to the frequency of Doppler-detected micro-
emboli [7].
Several clinical studies unravelled that cardiac bio-
marker elevations directly correlated with the extent of
myocardial necrosis [11]. In patients with pNSTEMI the
myocardial damage represents up to 5% of the left ven-
tricular mass [12].
The progressive contractile dysfunction results from
an inflammatory reaction to microinfarctions. Elevation
of high-sensitivity C-reactive protein (hs-CRP) levels
providing prognostic information for patients receiving
PCI [13] and could be derived directly from inflamma-
tion or from secondary reaction to microinfarctions due
to microembolization [14]. This inflammation marker
could be used as a predictor for early complications after
stent deployment [15].
Presentation of the hypothesis
The mouse monoclonal antibody abciximab against the
platelet receptor glycoprotein IIb/IIIa (GPIIb/IIIa) is
able to inhibit platelet aggregation by more than 80%
[16]. In patients with acute myocardial infarction abcix-
imab was able to improve myocardial microcirculation
and reduce infarct size due to dissolution of thrombi
and microemboli [17]. Therefore we hypothesize thatabciximab is a possible agent to reduce coronary micro-
embolization in patients with stable CAD undergoing
elective PCI.
Testing the hypothesis
The HITS-RP study is a prospective, double-blinded,
randomized, placebo controlled trial in patients with
coronary artery disease (CAD) undergoing PCI. The
study goal is to determine the efficacy of intravenous
abciximab bolus application with subsequent 12-hour
intravenous infusion in reducing high intensity transient
signals (HITS) compared to placebo. The trial is reg-
istered under www.drks-neu.uniklinik-freiburg.de/drks_web/:
DRKS00000603.
Primary and secondary outcome
The primary study end point of the HITS-RP study is
the incidence of HITS during PCI. Secondary endpoints
are changes in CFVR, cardiac biomarkers (cTNI, CK,
CK-MB) and hs-CRP in comparison to the initial values,
ECG changes, bleeding complications due to the add-
itional thrombocyte inhibiton, and any type of major ad-
verse cardiac or vascular event during one month
follow-up. Bleeding complications will be assessed
according to the GUSTO criteria (a-severe or life-threa-
tening; b-moderate; c-mild) [18].
Patient population
The prospective study will include 60 consecutive
patients with CAD and elective PCI. Recruitment will
commence in may 2012. The Institutional Ethics Com-
mittee of University Hospital of Jena approved the
study protocol.
Inclusion criteria
Patients are eligible for the study if they are between 18
and 80 years of age. Inclusion criteria are stable angina
pectoris and written informed consent.
Exclusion criteria
The exclusion criteria were (1) increase of cardiac mar-
kers before PCI, (2) left bundle-branch block, (3) ter-
minal renal insufficiency, (4) hypothyroidism, (5) skeletal
muscle injury, (6) chronic occluded target artery, (7) bi-
furcation lesion, (8) in-stent restenosis, (9) planned mul-
tivessel intervention, (10) side branch occlusion or (11)
prolonged vasospasm and (12) any contraindication for
antiplatelet medication.
Randomization
Patient randomization is performed centrally with a
randomization ratio of 1:1 (n = 30 patients per group).
Patients will be randomized by blockwise randomization
with a fixed block size of 6 using Datinf randList 1.2.
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rithm of Park and Miller with Bays-Durham correction.
Allocation concealment is done in the pharmacy. Medi-
cation will be delivered in black syringes with a label
only containing study name and patients number
(Figure 1).
Power calculation
Based on the results of previous studies [7] we expect 27
HITS on average in the placebo group and 18 HITS in
the treatment group. Assuming a standard deviation of
12 in both groups, we will need a sample size of 29
patients to detect the treatment effect with a power of
80% at a two-sided alpha-level of 0.05. To account for
drop-outs we have chosen to include 30 patients per
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Figure 1 ReoPro HITS flowchart.Patient treatment
All patients receive 100 mg acetylsalicylic acid once daily
before PCI and thereafter according to the standards of
good clinical practice. Those patients not already taking
clopidogrel medication will receive 600 mg immediately
after PCI and afterwards 75 mg once daily. A heparin
bolus of 70 IU Heparin/kg body weight is given follow-
ing the insertion of the arterial sheath. All other medica-
tion is given at the discretion of the attending
cardiologist. After diagnostic angiography with know-
ledge of the coronary anatomy patients are planned to
undergo balloon dilatation with implantation of a stent
for a single stenosis. The choice of stent (bare-metal or
drug-eluting stent) is left to the discretion of the attend-
ing cardiologist. Patients will be randomly assigned to
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of 0.25 mg/kg body weight 10 minutes before PCI fol-
lowed by a continuous infusion at 0.125 μg/kg/min
initiated immediately after the bolus and continued for
12 h. A Doppler guidewire is positioned 1 to 2 cm distal
to the stenosis for PCI. At this position the average peak
velocity (APV) is recorded. Before and after each inter-
ventional step CFVR is measured as the ratio of max-
imum APV and baseline APV. Maximum hyperemia will
be induced by intracoronary injection of 30–40 μg ad-
enosine. The number of HITS will be measured as previ-
ously described [7].
After PCI, removal of the sheath is performed accord-
ing to local practice. Care must be taken to ensure ad-
equate hemostasis.
After 12 and 24 h creatine kinase (CK), creatine kin-
ase-MB (CK-MB), cardiac troponin I (cTNI),
hemoglobin (Hb), hs-CRP will be determined and after
24 h also an ECG will be recorded. At 30-day follow-up
all cause mortality, myocardial infarction, angina pec-
toris, new congestive heart failure, and bleeding compli-
cations will be assessed. This is the end of the trial.
Data and statistical analysis
The primary end point will be analyzed according to the
intention-to-treat principle using the independent-sam-
ples t-test. In addition per-protocol analysis and to ad-
just for risk factors (such as diabetes, hypertension,
smoking, cholesterol level, sex) multivariate regression
analysis will be performed. The secondary endpoints are
compared using Student’s t-test, Mann–Whitney U test,
chi-square test and Fisher’s exact test as appropiate and
by multivariate regression models.
All data will be collected independently in a blinded
database by an external data management facility (2con-
duct clinical trials). A p-value of <0.05 will be consid-
ered as statistically significant. Data analysis will be
performed using SAS 9.3 (SAS Institute Inc.).
Discussion
Coronary microembolization is a frequent event in ische-
mic heart disease, occurring artificially during coronary
interventions. Especially patients with multivessel coron-
ary artery disease, more than 20 microemboli, and high in-
flation pressure during PCI are at risk for pNSTEMI [7].
Thus, the protocol of the HITS-RP study is focused on
patients undergoing elective PCI for stable CAD.
It is important to note that data for the use of filter
devices during PCI were disappointing and no significant
protection against microembolization was achieved in pre-
vious studies [19]. In consequence novel treatment strat-
egies of preventing patients from pNSTEMI are desired.
Numerous studies demonstrated the effect of anti-
platelet agents in patients with stable angina pectoris oracute coronary syndrome for attenuation of myocardial
damage and reduction of adverse events [20,21]. How-
ever, it is still unclear whether the respective agent is
able to reduce the formation of coronary microemboli.
The glycoprotein IIb/IIIa receptor antagonist tirofiban
reversibly suppressed HITS in the cerebrovascular cir-
culation [22]. Thus, this clinical study is designed to
identify a target for drug therapy of coronary micro-
embolization and its consequences. In previous clinical
trials, the benefits of abciximab infusion were achieved
at the risk of increased bleeding [16]. It is necessary to
mention that also the safety of abciximab infusion
when added to antiplatelet therapy with aspirin and
clopidogrel is an important question of the HITS-
RP study.
Limitations
Due to the small study size results will be interpreted
with caution and in case of reduction of HITS a larger
clinical trial will have to follow. Due to statistical rea-
sons, we do not expect a difference in the composite
major adverse cardiac event rate (death, reinfarction, tar-
get vessel revascularization, new congestive heart failure)
between the two study arms.
Clinical implications of the hypothesis
Clinical findings suggest that coronary microemboliza-
tion and pNSTEMI are frequent periprocedural compli-
cations. Relevant numbers of microemboli during
cardiac interventions could also be detected in the cere-
brovascular circulation [23].
Administration of abciximab could protect the myo-
cardium and maybe also the cerebrovascular system. It
may reduce the incidence of myocardial damage and also
the inflammatory reaction associated with myocyte ne-
crosis. Because of its ease administration and general
availability this treatment approach could have a high
potential in clinical practice.
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